AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03111732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475)
Description: 200 mg will be administered as an IV infusion on Day 1 of each 21 day cycle
Study NCT03111732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m(2) IV Infusion will be administered as an IV infusion on Day 1 of cycles 1-6
Study NCT03111732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 750 mg/m(2) will be administered orally twice a day on Days 1-14 of cycles 1-6
Study NCT02781701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue Trainer
Description: The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks.
Study NCT01903200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Oral
Study NCT02181140 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EUS guided FNA and fine needle punction
Description: punction of a suspect area by a EUS guided fine needle as well as pro core fine needle to evacuate histology and smear biologics
Study NCT03723044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG and occulometry
Description: Each participants will spend two sessions of EEG and occulometry during a visual cognitive task where she/her will be presented with multi-stable visual stimuli to gaze at for one or two minutes. Depending on the experimental conditions, the participant will provide or not her/his perceptual state (i.e. which stimulus has been perceived ).
Study NCT02125461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
Study NCT02125461 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
Study NCT03043469 — intervention group
Intervention type: OTHER
Intervention: Short-form survey instrument
Description: Questionnaire with questions about quality of life. Takes about 5 minutes to be completed.
Study NCT03043469 — intervention group
Intervention type: OTHER
Intervention: Demographic data
Description: height, weight, age, gender, list of comorbidities, health history, level of physical activity, medicines in use. Takes about 10 minutes to be completed.
Study NCT03043469 — intervention group
Intervention type: OTHER
Intervention: Hospital Anxiety and Depression Scale
Description: Questionnaire with questions about anxiety and depression. Takes about 5 minutes to be completed.
Study NCT03043469 — intervention group
Intervention type: OTHER
Intervention: Nijmegen questionnaire
Description: Answering questions about symptoms related to breathing. Takes about 5 minutes to be completed.
Study NCT03043469 — intervention group
Intervention type: OTHER
Intervention: The Self-evaluation of breathing questionnaire
Description: Answering questions about self-evaluation of breathing. Takes about 5 minutes to be completed
Study NCT00161421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: 24.5 mg load (3.5 mg x 7 capsulesDay -14 only) 0.5 mg daily (Day -13 to day -1)
Study NCT02811354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: oral administration as a single daily dose of 80 mg
Study NCT03135301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole plus metformin
Description: letrozole 5 milligram tablets plus metformin 850 milligram tablets
Study NCT03135301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: letrozole 5 milligram tablets
Study NCT03311061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DREAMS Curriculum
Description: Teen Pregnancy Prevention Curriculum as described in arm/group description.
Study NCT03311061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DREAMS Curriculum
Description: Teen Pregnancy Prevention Curriculum as described in arm/group description.
Study NCT02517554 — intervention group
Intervention type: BEHAVIORAL
Intervention: Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site
Description: Baseline and follow up survey
Study NCT02517554 — intervention group
Intervention type: BEHAVIORAL
Intervention: Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site
Description: Baseline and follow up surveys
Study NCT02517554 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient receives written information on how to find genetic services in their area
Description: Baseline and follow up surveys
Study NCT03110991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)
Description: Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)
Study NCT03110991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)
Description: Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)
Study NCT01926119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Study NCT01501786 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: control
Description: propofol 8mg/kg/h saline 0.24 ml/kg/h
Study NCT01501786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ket10
Description: propofol 6.4 mg/kg/h ketamine 10 microg/kg/min
Study NCT01501786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ket20
Description: propofol 4.8 mg/kg/h ketamine 20 microg/kg/min
Study NCT01116739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Description: Fluoride varnish will be administered by the COHS quarterly for 2 years.
Study NCT01116739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral health education
Description: Oral health education will be provided quarterly for 2 years. It will include information about how to mitigate the known risk factors for early childhood dental caries.
Study NCT03043469 — intervention group
Intervention type: OTHER
Intervention: six-minute exercise test
Description: Cycling against certain load in a bicycle for 6 minutes. Takes about 16 minutes to be completed together with indirect calorimetry, oxygen saturation monitoring, heart rate variability analysis and continuous monitoring of arterial blood pressure).
Study NCT01116739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental services delivered by the Indian Health Service.
Study NCT02645500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic health training and physical exercise messages
Description: The physical activity message arm includes a training workshop in relation to holistic health, and daily physical activity messages.
Study NCT02645500 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Holistic Health Training with healthy diet messages
Description: The healthy diet message arm includes a training workshop in relation to holistic health, and daily healthy diet messages.
Study NCT03487081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social regulation
Description: Participants will be instructed to help another person think about their negative events differently using an emotion regulation strategy called reappraisal.
Study NCT03487081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self regulation
Description: Participants will be instructed to think about their negative events by reframing the meaning of the event. This is a typical strategy in emotion regulation research known as reappraisal.
Study NCT01849003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-6615
Description: GS-6615 tablet(s) administered orally
Study NCT00392873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EAMD+Calories
Description: During the 12 month intervention, volunteers in the Increased calorie intake group will follow a modified dietary plan designed to achieve and maintain a target level of 20-30% above their previously determined baseline, in an effort to achieve a chronic energy surplus of +20-30% over their baseline energy requirements.
Study NCT02163369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peppermint and Lavender Essential Oils
Study NCT03566966 — intervention group
Intervention type: BIOLOGICAL
Intervention: Non-organ-specific Ab positive
Description: Antiviral administration and evaluation of SVR24 and side effects
Study NCT03566966 — intervention group
Intervention type: BIOLOGICAL
Intervention: Non-organ-specific Ab negative
Description: direct-acting antiviral agents
Study NCT01626040 — intervention group
Intervention type: DRUG
Intervention: polyethylene glycol powder
Description: A single group of children taking a polyethylene glycol powder preparation, dosage determined by patient weight, taken in one dose the day before colonoscopy
Study NCT01505062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR421869
Description: Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection
Study NCT03043469 — intervention group
Intervention type: OTHER
Intervention: Indirect calorimetry
Description: Breathing through a mask that measures levels of oxygen, carbon dioxide, breathing frequency and others (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
Study NCT03043469 — intervention group
Intervention type: OTHER
Intervention: Oxygen saturation monitoring
Description: The measurement of the amount of oxygen which is attached to haemoglobin molecules (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
Study NCT00388739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention: Budesonide
Description: Patients 1-5 years of age who are randomly assigned to the treatment arm will be given a one month supply as well as a prescription (for a 6 month supply) for Pulmicort respules (children with mild persistent disease will receive 0.25 mg bid whereas children with moderate or severe persistent disease will receive 0.5 mg bid).
Study NCT00388739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care: albuterol + systemic steroids
Description: All children (control and treatment arm) will be given a burst dose of steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day) at discharge from the ED. All children 1-5 years of age will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor.
Study NCT00388739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual care: albuterol + systemic steroids
Description: All children (control and treatment arm) will be given a burst dose of steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day) at discharge from the ED. All children 1-5 years of age will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor.
Study NCT02225886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
Study NCT03043469 — intervention group
Intervention type: OTHER
Intervention: Heart rate variability analysis
Description: Measurement of the variation in the beat-to-beat interval (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
Study NCT02225886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic Acid
Description: 300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
Study NCT00187161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin
Description: The additional information is contained in the Detailed Description section.
Study NCT03043469 — intervention group
Intervention type: OTHER
Intervention: Continuous measurement of arterial blood pressure
Description: Measurement of blood pressure based on the peripheral pulse using a finger cuff (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
Study NCT03689738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potato (Resistant Starch)
Description: Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g resistant starch (RS) per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
Study NCT03689738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHO-matched (Low-fiber, RS-free)
Description: Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
Study NCT02873546 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 2 session per day during 5 consecutive days. Subjects will be monitored during tDCS sessions for any side effects or adverse events.
Study NCT02873546 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 2 session per day during 5 consecutive days. Subjects will be monitored during tDCS sessions for any side effects or adverse events.
Study NCT03920605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
Study NCT03920605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2a
Description: Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
Study NCT03920605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2b
Description: Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
Study NCT01541605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate
Description: tablets for oral use
Study NCT01541605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets for oral use
Study NCT00410891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gatifloxacin
Study NCT02188446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational programme for smoking and alcohol cessation
Description: 5 meetings within 6 weeks containing education and pharmacologic support
Study NCT00934063 — intervention group
Intervention type: DRUG
Intervention: somatropin
Description: For s.c. (under the skin) injection. Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT01352351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Description: * Breastfeeding counseling during monthly microcredit meetings~* Weekly cell phone messages about breastfeeding
Study NCT00538525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin, Docetaxel, Cisplatin
Description: Doxorubicin, Docetaxel, Cisplatin
Study NCT04588532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22
Description: Bovine Adrenal Medulla will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
Study NCT04588532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histamine
Description: histamine will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
Study NCT04588532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cowhage (Mucuna Pruriens)
Description: cowhage spicules will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
Study NCT04588532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxepin
Description: Doxepin cream (antihistamine) will be applied in 4 areas on the volar forearm
Study NCT02597153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone HCL Liposome Injection
Study NCT03868982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist
Description: NAVA uses the diaphragm activity to deliver mechanical ventilation
Study NCT02861378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine mesylate
Description: Injection of 1ml at lidocaine injection site
Study NCT02861378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Injection of 1ml of physiologic saline water at injection site
Study NCT02196571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Exercise
Study NCT00657904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 150mg daily
Study NCT03043469 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function test
Description: Breathing through a mouth-piece in many different ways in order to measure the function of the lungs (non-invasively).
Study NCT03043469 — intervention group
Intervention type: OTHER
Intervention: Respiratory muscle function
Description: Breathing through a mouth-piece in many different ways in order to measure the function of the respiratory muscles (non-invasively).
Study NCT03043469 — intervention group
Intervention type: OTHER
Intervention: Manual assessment of respiratory motion
Description: Measure of the movements of the thorax while the participant is breathing (non-invasively).
Study NCT03043469 — intervention group
Intervention type: OTHER
Intervention: Breath-hold test
Description: Holding the breath a few times for as long as possible.
Study NCT03043469 — intervention group
Intervention type: OTHER
Intervention: Physical Activity monitoring
Description: Wearing a light-weight activity monitor to be wore on the hip for 7 consecutive days during, at least, 8 hours per day.
Study NCT03043469 — intervention group
Intervention type: OTHER
Intervention: Asthma Control Questionnaire
Description: Only for asthmatics: answering questions about the control the participant has over this respiratory condition/symptoms.
Study NCT00934063 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Control group not receiving treatment
Study NCT03009695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency repetitive dTMS
Description: Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically high-frequency rTMS (18 Hz) enhances cortical excitability.
Study NCT03009695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency repetitive dTMS
Description: Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically low-frequency rTMS (1 Hz) inhibits cortical excitability.